Cemsidomide Data Presented at American Society of Hematology (ASH) Annual Meeting Support Best-in-Class Profile; Program Advancing to Next Phase ...

Philippa Salter, Managing Neurology Analyst at GlobalData, said that Eisai/Biogen’s Leqembi (lecanemab) and Eli Lilly’s Kisunla (donanemab) will become the top-selling drugs for Alzheimer’s, and “will ...

The risk of developing dementia may be much higher than previously thought, a study published Monday in the journal Nature ...

ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...

Biogen Inc. (Nasdaq: BIIB) – today announced the appointment of Adam Feire, Ph.D., as Head of Business Development and External Innovation. Mr. Feire reports to Adam Keeney, Ph.D., Executive Vice ...

Leading firms such as Biogen Inc., Eli Lilly & Co., Novo Nordisk A/S ... Some of the Content on this website may be sponsored ...

Multiple Sclerosis companies are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., ...

The best website builders let you make pages with more design flexibility than anything you'll find on social media, though with fewer tools than traditional web hosting services. We've been ...

Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Mollie Leoni, ...

According to latest analysis by Report Ocean, the global antibody drugs market is poised to grow by USD 91 billion during 2022-2028, progressing at a CAGR of 9.7% during the forecast period. Request ...

Read Less The best website builders allow users to create customised websites for their businesses or personal use quickly and easily, even if their design skills are limited. To compile our list ...

Piper Sandler downgraded Biogen (NASDAQ:BIIB) to neutral from overweight on Thursday, citing, among other things, the company's challenges in establishing its presence in the market for Alzheimer ...